Literature DB >> 10221303

Treatment guidelines for primary nonretentive encopresis and stool toileting refusal.

B R Kuhn1, B A Marcus, S L Pitner.   

Abstract

Nonretentive encopresis refers to inappropriate soiling without evidence of fecal constipation and retention. This form of encopresis accounts for up to 20 percent of all cases. Characteristics include soiling accompanied by daily bowel movements that are normal in size and consistency. An organic cause for nonretentive encopresis is rarely identified. The medical assessment is usually normal, and signs of constipation are noticeably absent. A full developmental and behavioral assessment should be made to establish that the child is ready for intervention to correct encopresis and to identify any barriers to success, particularly disruptive behavior problems. Successful interventions depend on the presence of soft, comfortable bowel movements and addressing toilet refusal behavior. Daily scheduled positive toilet sits are recommended. Incentives may be used to reinforce successful defecation during these sits. A plan for management of stool withholding should be agreed on by the parents/caretakers and the family physician before intervention.

Entities:  

Mesh:

Year:  1999        PMID: 10221303

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

1.  Treating non-retentive encopresis with rewarded scheduled toilet visits.

Authors:  Richard E Boles; Michael C Roberts; Eric M Vernberg
Journal:  Behav Anal Pract       Date:  2008

Review 2.  Defecation-Specific Behavior in Children with Functional Defecation Issues: A Systematic Review.

Authors:  Isabelle Beaudry-Bellefeuille; Debbie Booth; Shelly J Lane
Journal:  Perm J       Date:  2017

3.  Psychomotor approach in children affected by nonretentive fecal soiling (FNRFS): a new rehabilitative purpose.

Authors:  Maria Esposito; Francesca Gimigliano; Maria Ruberto; Rosa Marotta; Beatrice Gallai; Lucia Parisi; Serena Marianna Lavano; Giovanni Mazzotta; Michele Roccella; Marco Carotenuto
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-19       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.